Keith G Tolman

Summary

Affiliation: University of Utah
Country: USA

Publications

  1. ncbi request reprint Hepatotoxicity of the thiazolidinediones
    Keith G Tolman
    Division of Gastroenterology, Department of Internal Medicine, University of Utah School of Medicine, 30 N 1900 E RM 4R118 SOM Salt Lake City, UT 84132, USA
    Clin Liver Dis 7:369-79, vi. 2003
  2. ncbi request reprint Narrative review: hepatobiliary disease in type 2 diabetes mellitus
    Keith G Tolman
    University of Utah and University Hospitals and Clinics, Salt Lake City, Utah 84132, USA
    Ann Intern Med 141:946-56. 2004
  3. ncbi request reprint Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers
    Keith G Tolman
    University of Utah School of Medicine, Salt Lake City, Utah, USA
    Clin Drug Investig 26:21-8. 2006
  4. ncbi request reprint Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease
    Keith G Tolman
    Division of Gastroenterology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
    Diabetes Care 30:734-43. 2007
  5. doi request reprint Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US
    Keith G Tolman
    University of Utah, Salt Lake City, Utah, USA
    Drug Saf 32:787-800. 2009
  6. ncbi request reprint The liver and lovastatin
    Keith G Tolman
    University of Utah School of Medicine, Salt Lake City, Utah 84132, USA
    Am J Cardiol 89:1374-80. 2002
  7. ncbi request reprint Reply to Dr. Dujovne's editorial
    Keith G Tolman
    Am J Cardiol 89:1452. 2002
  8. ncbi request reprint The therapeutic use of acetaminophen in patients with liver disease
    Gordon D Benson
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 401 Haddon Avenue, Camden, NJ 08103, USA
    Am J Ther 12:133-41. 2005

Detail Information

Publications8

  1. ncbi request reprint Hepatotoxicity of the thiazolidinediones
    Keith G Tolman
    Division of Gastroenterology, Department of Internal Medicine, University of Utah School of Medicine, 30 N 1900 E RM 4R118 SOM Salt Lake City, UT 84132, USA
    Clin Liver Dis 7:369-79, vi. 2003
    ..All of the thiazolidinediones cause ALT elevations; however, ALT monitoring for hepatotoxicity does not appear to prevent serious liver disease nor reduce patient risk...
  2. ncbi request reprint Narrative review: hepatobiliary disease in type 2 diabetes mellitus
    Keith G Tolman
    University of Utah and University Hospitals and Clinics, Salt Lake City, Utah 84132, USA
    Ann Intern Med 141:946-56. 2004
    ....
  3. ncbi request reprint Comparison of the effects of single and repeated oral doses of lansoprazole and rabeprazole on ambulatory 24-hour intragastric pH in healthy volunteers
    Keith G Tolman
    University of Utah School of Medicine, Salt Lake City, Utah, USA
    Clin Drug Investig 26:21-8. 2006
    ....
  4. ncbi request reprint Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease
    Keith G Tolman
    Division of Gastroenterology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
    Diabetes Care 30:734-43. 2007
  5. doi request reprint Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US
    Keith G Tolman
    University of Utah, Salt Lake City, Utah, USA
    Drug Saf 32:787-800. 2009
    ..We conducted a randomized, long-term, double-blind, hepatic safety study at 171 centres in the US in which 2097 patients with type 2 diabetes received either pioglitazone or glibenclamide (glyburide)...
  6. ncbi request reprint The liver and lovastatin
    Keith G Tolman
    University of Utah School of Medicine, Salt Lake City, Utah 84132, USA
    Am J Cardiol 89:1374-80. 2002
    ..In fact, it may increase patient risk because of needless discontinuation of cholesterol-lowering therapy for false-positive results in patients who are benefiting from treatment...
  7. ncbi request reprint Reply to Dr. Dujovne's editorial
    Keith G Tolman
    Am J Cardiol 89:1452. 2002
  8. ncbi request reprint The therapeutic use of acetaminophen in patients with liver disease
    Gordon D Benson
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, 401 Haddon Avenue, Camden, NJ 08103, USA
    Am J Ther 12:133-41. 2005
    ....